Leerink Partners Initiates Coverage On Cartesian Therapeutics with Outperform Rating, Announces Price Target of $39
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Thomas Smith initiates coverage on Cartesian Therapeutics (NASDAQ:RNAC) with an Outperform rating and a price target of $39.
April 23, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners initiated coverage on Cartesian Therapeutics with an Outperform rating and a price target of $39.
The initiation of coverage by Leerink Partners with an Outperform rating and a significant price target suggests a positive outlook for Cartesian Therapeutics. This endorsement by a reputable analyst could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100